LP
PRCT icon

Longaeva Partners’s Procept Biorobotics PRCT Stock Holding History

Longaeva Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Sell
107,018
-67,982
-39% -$1.7M 0.05% 242
2026
Q1 		$4.38M Buy
+175,000
New +$4.93M 0.16% 121

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Longaeva Partners's PRCT Position: Q2 2026 in Review

Longaeva Partners reduced its Procept Biorobotics (PRCT) stake by 39% in Q2 2026, selling an estimated $1.7M and leaving 107,018 shares worth $2.42M. The position accounts for 0.05% of the portfolio, ranked #242.

Longaeva Partners first reported a position in PRCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.38M in Q1 2026. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Longaeva Partners held 107,018 shares of Procept Biorobotics worth $2.42M as of Q2 2026.
  • Longaeva Partners sold 67,982 Procept Biorobotics shares in Q2 2026, an estimated $1.7M.
  • Procept Biorobotics made up 0.05% of Longaeva Partners's portfolio in Q2 2026, its #242 holding.
  • Longaeva Partners first reported a position in Procept Biorobotics in Q1 2026 and has held it in 2 quarters since.
  • Longaeva Partners's Procept Biorobotics position peaked at $4.38M in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.